Acute Erythroderma in a Patient Receiving TNF-alpha-Blocking Therapy for Hidradenitis Suppurativa

被引：5

作者：

Benhadou, Farida ^{[1
]}

Hellgren, Guillaume ^{[1
]}

Willaert, Fabienne ^{[1
]}

del Marmol, Veronique ^{[1
]}

机构：

[1] Univ Libre Bruxelles, Erasme Hosp, Dermatol, Brussels, Belgium

来源：

CASE REPORTS IN DERMATOLOGY | 2018年 / 10卷 / 01期

关键词：

TNF-alpha; Adalimumab; Hidradenitis suppurativa; Psoriasis; Erythroderma;

D O I：

10.1159/000485911

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Tumor necrosis factor-alpha (TNF-alpha) normally binds to TNF-alpha receptors, leading to the inflammatory response of autoimmune diseases. Adalimumab is a TNF-inhibiting, anti-inflammatory, biological medication which binds to TNF-alpha, thus reducing this inflammatory response. The use of TNF-alpha-inhibiting medication, such as adalimumab, being the first FDA-approved treatment for hidradenitis suppurativa, has drastically changed the management of dermatological diseases. One rarely reported manifestation that occurs as a side effect associated with the use of TNF-alpha-blocking agents is erythroderma. This study, for the first time, reports the case of a patient suffering from hidradenitis suppurativa with concomitant psoriasis, who developed a severe and acute erythrodermic rash after the start of adalimumab therapy. (C) 2018 The Author(s) Published by S. Karger AG, Basel

引用

页码：7 / 12

页数：6

共 15 条

[1] Injection site reactions to TNF-α blocking agents with positive skin tests [J].

Benucci, M. ;

Manfredi, M. ;

Demoly, P. ;

Campi, P. .

ALLERGY, 2008, 63 (01) :138-139

[2] Adverse Cutaneous Reactions Induced by TNF-α Antagonist Therapy [J].

Borras-Blasco, Joaquin ;

Navarro-Ruiz, Andres ;

Borras, Consuelo ;

Castera, Elvira .

SOUTHERN MEDICAL JOURNAL, 2009, 102 (11) :1133-1140

[3] Erythroderma. A clinical and etiological study of 103 patients [J].

Cesar, Artur ;

Cruz, Maria ;

Mota, Alberto ;

Azevedo, Filomena .

JOURNAL OF DERMATOLOGICAL CASE REPORTS, 2016, 10 (01) :1-9

[4]

Cordoro K M, 2007, Skin Therapy Lett, V12, P4

[5]

Corominas M, 2014, J INVEST ALLERG CLIN, V24, P212

[6] Generalized erythroderma and palmoplantar hyperkeratosis in a patient receiving TNF-alpha antagonist therapy [J].

Dunst-Huemer, Karin M. ;

Scheurecker, Christine ;

Auboeck, Josef .

JOURNAL OF CUTANEOUS PATHOLOGY, 2013, 40 (09) :855-856

[7] Exfoliative erythroderma after tumor necrosis factor-α inhibitor therapy [J].

el-Azhary, Rokea A. ;

Lehman, Julia S. .

INTERNATIONAL JOURNAL OF DERMATOLOGY, 2016, 55 (04) :E214-E215

[8]

Gupta A K, 2016, Skin Therapy Lett, V21, P1

[9] The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis [J].

Katugampola, R. P. ;

Lewis, V. J. ;

Finlay, A. Y. .

BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (05) :945-950

[10] Adalimumab: A Review in Hidradenitis Suppurativa [J].

Kim, Esther S. ;

Garnock-Jones, Karly P. ;

Keam, Susan J. .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2016, 17 (05) :545-552

← 1 2 →